# Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy

> **NCT03193788** · PHASE3 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 74 (estimated)

## Conditions studied

- Bladder Cancer
- Ureter Cancer
- Transitional Cell Carcinoma

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** Folic Acid
- **DRUG:** Vitamin B12 Injection
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03193788
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2019-12
- **Final completion:** 2020-06
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2017-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193788, "Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03193788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*